Abstract:Background
CHEK2 has been recognized as a breast cancer risk gene with moderate effect. Women who have previously tested negative for a BRCA1/2 gene germline pathogenic variant may benefit from additional genetic testing for the CHEK2 c.1100del pathogenic variant. The aims of this study were: 1) to assess the uptake of an active approach by recontacting BRCA1/2-negative women for additional CHEK2 c.1100del testing on stored DNA-samples and 2) to explore patients’ experiences with this approach.… Show more
“…These participants did not express negative feelings about being recontacted despite the unexpectedness of the contact and the potential past di culties of coping with a TOP. Previous studies also con rmed mainly positive attitudes towards recontacting (17)(18)(19)(20)(21)26). However, the number of qualitative studies exploring in depth the experience of being recontacted is scarce.…”
Section: Discussionmentioning
confidence: 79%
“…A few studies have been published in patients with different genetic conditions, more speci cally in deceased children with a mitochondrial disorder (19), children with intellectual disability (18), hereditary cancer patients (20) and patients with varying genetic disorders (21). In general, these empirical studies describe a mainly positive feeling (17)(18)(19)(20)(21), however more indepth exploration of patients' experiences with recontacting is lacking. On the contrary, personal motivations for pursuing genetic testing have been extensively investigated in other contexts such as patients with Huntington's disease and hereditary cancer syndromes.…”
Section: Introductionmentioning
confidence: 99%
“…However, studies from a patient perspective are rather scarce. A few studies have been published in patients with different genetic conditions, more speci cally in deceased children with a mitochondrial disorder (19), children with intellectual disability (18), hereditary cancer patients (20) and patients with varying genetic disorders (21). In general, these empirical studies describe a mainly positive feeling (17)(18)(19)(20)(21), however more indepth exploration of patients' experiences with recontacting is lacking.…”
Rapid advances in genetic testing techniques increase the possibility of finding a genetic diagnosis. In the case of couples who underwent a termination of pregnancy (TOP) due to foetal congenital malformations, these techniques might reveal the cause and meet the parent's need to know. The aim of this qualitative study is to explore the experiences of couples with being recontacted after TOP for congenital malformations, as well as the reasons for participating. A retrospective cohort of 31 couples was recontacted for additional genetic testing by sending a standardized letter followed by a telephone call. Fourteen couples (45%) agreed to participate. Data were collected through semi-structured interviews at the genetics department of the hospital (UZ Brussel). Interviews were audiotaped, transcribed and analysed using thematic analysis. We found that, despite the years that passed since the TOP, participants were still interested to perform novel genetic testing. They appreciated that the initiative for recontacting came from the medical team and described it as a sensitive approach. Both intrinsic (searching for answers for themselves and their children) and extrinsic motivators (contributing to science and helping other parents) were identified as important drivers of participation. These results show that, even after several years, many couples are still interested and motivated to be recontacted for further genetic testing. The results of this study can offer guidance in current debate on recontacting patients in the field of genetics.
“…These participants did not express negative feelings about being recontacted despite the unexpectedness of the contact and the potential past di culties of coping with a TOP. Previous studies also con rmed mainly positive attitudes towards recontacting (17)(18)(19)(20)(21)26). However, the number of qualitative studies exploring in depth the experience of being recontacted is scarce.…”
Section: Discussionmentioning
confidence: 79%
“…A few studies have been published in patients with different genetic conditions, more speci cally in deceased children with a mitochondrial disorder (19), children with intellectual disability (18), hereditary cancer patients (20) and patients with varying genetic disorders (21). In general, these empirical studies describe a mainly positive feeling (17)(18)(19)(20)(21), however more indepth exploration of patients' experiences with recontacting is lacking. On the contrary, personal motivations for pursuing genetic testing have been extensively investigated in other contexts such as patients with Huntington's disease and hereditary cancer syndromes.…”
Section: Introductionmentioning
confidence: 99%
“…However, studies from a patient perspective are rather scarce. A few studies have been published in patients with different genetic conditions, more speci cally in deceased children with a mitochondrial disorder (19), children with intellectual disability (18), hereditary cancer patients (20) and patients with varying genetic disorders (21). In general, these empirical studies describe a mainly positive feeling (17)(18)(19)(20)(21), however more indepth exploration of patients' experiences with recontacting is lacking.…”
Rapid advances in genetic testing techniques increase the possibility of finding a genetic diagnosis. In the case of couples who underwent a termination of pregnancy (TOP) due to foetal congenital malformations, these techniques might reveal the cause and meet the parent's need to know. The aim of this qualitative study is to explore the experiences of couples with being recontacted after TOP for congenital malformations, as well as the reasons for participating. A retrospective cohort of 31 couples was recontacted for additional genetic testing by sending a standardized letter followed by a telephone call. Fourteen couples (45%) agreed to participate. Data were collected through semi-structured interviews at the genetics department of the hospital (UZ Brussel). Interviews were audiotaped, transcribed and analysed using thematic analysis. We found that, despite the years that passed since the TOP, participants were still interested to perform novel genetic testing. They appreciated that the initiative for recontacting came from the medical team and described it as a sensitive approach. Both intrinsic (searching for answers for themselves and their children) and extrinsic motivators (contributing to science and helping other parents) were identified as important drivers of participation. These results show that, even after several years, many couples are still interested and motivated to be recontacted for further genetic testing. The results of this study can offer guidance in current debate on recontacting patients in the field of genetics.
“…However, of the 14 studies that included the CHEK2 gene for screening in this review, only three were identified the c.1100delC variant [ 16 , 18 , 44 ]. This mutation has been described in less heterogeneous populations, as in studies conducted in the Netherlands that described the increased risk of breast cancer observed in patients with CHEK2 1100delC and another study that reported 4% of their tested patients carrying this pathogenic variant [ 64 , 65 ]. Studies show that carriers with a family history of breast cancer are at 2–3 times greater risk when breast cancer is associated with the CHEK2 c.1100delC mutation [ 66 ].…”
Background
A detailed understanding of the genetic basis of cancer is of great interest to public health monitoring programs. Although many studies have been conducted in Brazil, a global view on the molecular profile related to hereditary breast and ovarian cancer (HBOC) in this large and heterogeneous population is lacking.
Methods
A systematic review following the PRISMA guidelines was conducted in three electronic databases (PubMed, BIREME and SciELO). Brazilian studies covering molecular analysis of genes related to HBOC, published until December 2023, were considered.
Results
We identified 35 original studies that met all the inclusion criteria. A total of 137 distinct mutations were found in the BRCA1 gene, but four of them corresponded to 44.5% of all mutations found in this gene. The c.5266dupC BRCA1 mutation was responsible for 26.8% of all pathogenic mutations found in the BRCA1 gene in patients with clinical criteria for HBOC from the Brazilian population. Considering all studies that track this mutation in the BRCA1 gene, we found a frequency of 2% (120/6008) for this mutation in Brazilian patients. In the BRCA2 gene, the four most frequent mutations corresponded to 29.2% of pathogenic mutations. Even though it was tracked by few studies, the c.156_157insAlu mutation was responsible for 9.6% of all pathogenic mutations reported in the BRCA2 gene. Seventeen studies found pathogenic mutations in other non-BRCA genes, the c.1010G > A mutation in the TP53 gene being the most frequent one. Considering all studies that screened for this specific mutation in patients with the clinical criteria for HBOC, the frequency of c.1010G > A was estimated at 1.83% (61/3336).
Conclusions
Despite significant molecular heterogeneity among mutations in HBOC patients from Brazil, three mutations deserve to be highlighted, c.5266dupC, c.156_157insAlu and c.1010G > A in the BRCA1, BRCA2 and TP53 genes, respectively. With more than 200 records, these three mutations play a vital role in the pathology of breast and ovarian cancer in Brazil. The data collected shed light on the subject, but there is still not enough data from certain subpopulations.
ObjectiveThe purpose of this study was to recontact individuals with clinically actionable test results identified through a retrospective research study and to provide a framework for laboratories to recontact patients.MethodsGenetic testing was conducted on 2977 individuals originally referred forBRCA1andBRCA2hereditary breast and ovarian cancer testing that had a negative genetic test result. A gene panel was used to identify pathogenic variants in known or newly discovered genes that could explain the underlying cause of disease; however, analysis was restricted toPALB2for the purposes of this study. A patient recontact decision tree was developed to assist in the returning of updated genetic test results to clinics and patients.ResultsNovel clinically actionable pathogenic variants were identified in thePALB2gene in 18 participants (0.6%), the majority of whom were recontacted with their new or updated genetic test results. Eight individuals were unable to be recontacted; five individuals had already learnt about their new or updated findings from genetic testing outside the context of this study; three individuals prompted cascade testing in family members; two individuals were deceased.ConclusionNovel pathogenic variants inPALB2were identified in 18 individuals through retrospective gene panel testing. Recontacting these individuals regarding these new or updated findings had a range of outcomes. The process of conveying genomic results within this framework can be effectively accomplished while upholding patient autonomy, potentially leading to advantageous outcomes for patients and their families.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.